IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

Sponsor
Masonic Cancer Center, University of Minnesota (Other)
Overall Status
Completed
CT.gov ID
NCT01885897
Collaborator
(none)
33
Enrollment
3
Locations
1
Arm
79.6
Actual Duration (Months)
11
Patients Per Site
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a multi-center, phase I/II clinical trial for patients who have relapsed more than 60 day after allogeneic transplant for a hematologic malignancy. The study consists of two phases. The dose finding phase is a modified version of a phase I trial and the extended phase is a modified version of a phase II trial.

The primary objective of the dose finding phase is to determine the maximum tolerated, minimum efficacious dose (MTD/MED) of a interleukin-15 (IL-15) super agonist complex (ALT-803) when given once weekly for 4 weeks in the outpatient setting. The study will follow a standard 3+3 design of dose escalation for toxicity with an added feature of stopping early if efficacy is confirmed. There are six dose levels of ALT-803 for to determine the MTD/MED: 1, 3, 6, 10, 20, and 30 mcg/kg.

Once the MTD/MED for ALT-803 is determined, this cohort will be used in the extended phase. The primary goal of this extended phase is to study the potential efficacy of ALT-803 in this patient population. Efficacy will be measured using rates of remission induction. An optimal Simon's two-stage design will be used in this phase. Stage 1 will enroll 14 patients (including the 6 patients treated at the MTD/MED during the dose finding phase). If 3 or more of these 14 patients respond to ALT-803, the trial will move to stage 2 and enroll an additional 23 patients. If 2 or fewer respond, the study will terminate enrollment early.

Study Design

Study Type:
Interventional
Actual Enrollment :
33 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation
Actual Study Start Date :
Nov 11, 2013
Actual Primary Completion Date :
Jul 1, 2019
Actual Study Completion Date :
Jul 1, 2020

Arms and Interventions

ArmIntervention/Treatment
Experimental: Study treatment

Weekly dose of ALT-803 at assigned dose, ranging from 1mcg/kg to 30 mcg/kg (based on phase 1 dose escalation schedule,) IV once a week for 4 weeks.

Biological: ALT-803
Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.

Outcome Measures

Primary Outcome Measures

  1. Number of Participants With Dose Limiting Toxicity (DLT) Events [4 weeks]

    The Dose Limiting Toxicity (DLT) is defined as (during first treatment cycle only): any treatment-emergent grade 3 non-hematologic toxicity lasting more than 48 hours (refer to section 6.2.1.1 for full definition) any treatment-emergent grade 4 or 5 non-hematologic toxicity of any duration grade III or IV acute GVHD within 6 weeks after the first ALT-803 dose Maximum Tolerated Dose (MTD) is defined as the dose level where ≤ 1 out of 6 patients has DLT during the first treatment cycle

  2. Number of Participants Experiencing Potential Efficacy of ALT 803 [4 months]

    The potential efficacy of ALT-803 in this patient population is measured by the responses based on bone marrow examination 1 and 3 months after the last dose of ALT-803. Response was defined as follows: for AML and myelodysplastic syndromes (MDS) using the International Working Group modified criteria, non-Hodgkin lymphoma, and multiple myeloma using the International Myeloma Working Group Uniform Response Criteria, and acute lymphoblastic leukemia using protocol-specified criteria.

Secondary Outcome Measures

  1. Number of Participants With Excessive Toxicity [4 weeks]

    To evaluate the safety of the ALT-803 when administered on this schedule. Excessive toxicity is defined as having a grade 3-5 non-hematologic, non-relapse and non-infectious toxicity (except fevers alone) based on the NCI's CTCAE version 4.

  2. Number of Participants With Incidence of Acute Graft Versus Host Disease [100 days]

  3. Number of Participants With Incidence of Chronic Graft Versus Host Disease [1 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Relapse after previous allogeneic stem cell transplant for one of the following hematologic malignancies (acute myelogenous leukemia, acute lymphoblastic leukemia,myelodysplastic syndromes, lymphoma, myeloma, Chronic lymphocytic Leukemia, chronic myelogenous leukemia):

  • For non-CML, relapse will be defined based on disease specific morphologic criteria from a bone marrow biopsy and aspirate or recurrence of disease specific cytogenetics. For disease specific definition of relapse, see appendix III. Relapse can be determined morphologically. Equivocal results for relapse should result in a repeated test after an appropriate time interval (suggested 1 month) to determine eligibility.

  • For CML, relapse will be defined as any cytogenetic evidence of a Philadelphia chromosome or persistence of BCR/ABL rearrangements by molecular testing on at least two measurements over a 6 month interval. If cytogenetics are normal and there is PCR evidence of a BCR/ABL fusion, patients will be eligible if they have evidence of a quantitative increase in CML measured either by quantitative PCR or by fluorescent in situ hybridization (FISH).

For Chronic Phase CML patients only:
  • must have failed (no response in 3 months or incomplete response at 6 months) or refused treatment with a tyrosine-kinase inhibitor (TKI)

  • must have failed (defined as incomplete response or relapse) or refused DLI

  • Relapse must have occurred ≥ 60 days after transplant

  • Prior DLI is allowed, however not within the 30 days before the 1st dose of ALT-803

  • Minimum donor chimerism of 10%

  • ≥ 18 years of age

  • Karnofsky performance status ≥ 70% (appendix II)

  • Adequate organ function within 14 days (30 days for cardiac and pulmonary) of enrollment defined as:

  • Creatinine: ≤ 2.0 mg/dL

  • Hepatic: SGOT/SGPT < 5 x upper limit of institutional normal (ULN)

  • Thyroid Function: Thyroid Stimulating Hormone (TSH) within institutional normal range - patients with thyroid disease are eligible if euthyroid on suppressive or replacement therapy

  • Pulmonary: PFTs > 50% of predicted

  • Cardiac: LVEF by ECHO or MUGA > 40%

  • Ability to be off prednisone and other immunosuppressive drugs for at least 30 day before first dose of study drug

  • Patient agrees to stay within a reasonable distance (i.e. 30 miles) of the study site for the duration of the study treatment and for a minimum of 48 hours after the last dose and has a dedicated care giver as is standard practice for BMT outpatient care

  • Women of child bearing potential and men with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy

  • Voluntary written consent

Exclusion Criteria:
  • Post-transplant lymphoproliferative diseases (often referred to as EBV-associated lymphomas)

  • Known active CNS leukemia or lymphoma - patients with previously treated CNS disease is permitted if neurologically stable with no ongoing or anticipated need for steroid therapy are eligible

  • Ongoing active acute or chronic GVHD requiring immunosuppressive therapy or signs of aGVHD or cGVHD requiring treatment

  • Pregnant or lactating - Women of child bearing potential must have a negative pregnancy test within 14 days of study treatment start

  • Class II or greater New York Heart Association Functional Classification criteria (appendix II) or serious cardiac arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmia requiring chronic therapy

  • Marked baseline prolongation of QT/QTc interval (e.g. demonstration of a QTc interval greater than 500 milliseconds)

  • New progressive pulmonary infiltrates on screening chest x-ray or chest CT scan for which evaluation with bronchoscopy is not feasible. Infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections).

  • Active bacterial, fungal, or viral infections - all prior infections must have resolved following optimal therapy

  • Positive hepatitis C serology or active hepatitis B infection because of the risk of hepatic inflammation and the possible confounding of drug toxicity assessment - chronic asymptomatic viral hepatitis is allowed

  • HIV positive because the effect of IL-15 viral loads, HIV immunity, and infectivity of proliferating T cells is unknown

  • History of severe asthma, presently on chronic medications (a history of mild asthma not requiring therapy is eligible)

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1Masonic Cancer Center, University of MinnesotaMinneapolisMinnesotaUnited States55455
2Washington UniversitySaint LouisMissouriUnited States63110
3University of PennsylvaniaPhiladelphiaPennsylvaniaUnited States19104

Sponsors and Collaborators

  • Masonic Cancer Center, University of Minnesota

Investigators

  • Principal Investigator: Jeffrey S. Miller, MD, Masonic Cancer Center, University of Minnesota

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT01885897
Other Study ID Numbers:
  • 2012LS023
  • HM2013-12
First Posted:
Jun 25, 2013
Last Update Posted:
Aug 12, 2020
Last Verified:
Jul 1, 2020

Study Results

Participant Flow

Recruitment Details
Pre-assignment Detail
Arm/Group TitleALT-803, IV, 1 mcg/kgALT-803, IV, 3 mcg/kgALT-803, IV, 6 mcg/kgALT-803, IV, 10 mcg/kgALT-803, SQ, 6 mcg/kgALT-803, SQ, 10 mcg/kg
Arm/Group DescriptionWeekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose subcutaneously, once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose , subcutaneously, once a week for 4 weeks.
Period Title: Overall Study
STARTED634389
COMPLETED634389
NOT COMPLETED000000

Baseline Characteristics

Arm/Group TitleALT-803, IV, 1 mcg/kgALT-803, IV, 3 mcg/kgALT-803, IV, 6 mcg/kgALT-803, IV, 10 mcg/kgALT-803, SQ, 6 mcg/kgALT-803, SQ, 10 mcg/kgTotal
Arm/Group DescriptionWeekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose subcutaneously, once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose , subcutaneously, once a week for 4 weeks.Total of all reporting groups
Overall Participants63438933
Age (Count of Participants)
<=18 years
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
Between 18 and 65 years
4
66.7%
2
66.7%
1
25%
3
100%
6
75%
6
66.7%
22
66.7%
>=65 years
2
33.3%
1
33.3%
3
75%
0
0%
2
25%
3
33.3%
11
33.3%
Sex: Female, Male (Count of Participants)
Female
3
50%
1
33.3%
1
25%
2
66.7%
4
50%
5
55.6%
16
48.5%
Male
3
50%
2
66.7%
3
75%
1
33.3%
4
50%
4
44.4%
17
51.5%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
Not Hispanic or Latino
6
100%
3
100%
4
100%
2
66.7%
7
87.5%
9
100%
31
93.9%
Unknown or Not Reported
0
0%
0
0%
0
0%
1
33.3%
1
12.5%
0
0%
2
6.1%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
Asian
0
0%
0
0%
0
0%
1
33.3%
0
0%
0
0%
1
3%
Native Hawaiian or Other Pacific Islander
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
Black or African American
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
White
6
100%
3
100%
4
100%
2
66.7%
7
87.5%
9
100%
31
93.9%
More than one race
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
Unknown or Not Reported
0
0%
0
0%
0
0%
0
0%
1
12.5%
0
0%
1
3%
Region of Enrollment (participants) [Number]
United States
6
100%
3
100%
4
100%
3
100%
8
100%
9
100%
33
100%

Outcome Measures

1. Primary Outcome
TitleNumber of Participants With Dose Limiting Toxicity (DLT) Events
DescriptionThe Dose Limiting Toxicity (DLT) is defined as (during first treatment cycle only): any treatment-emergent grade 3 non-hematologic toxicity lasting more than 48 hours (refer to section 6.2.1.1 for full definition) any treatment-emergent grade 4 or 5 non-hematologic toxicity of any duration grade III or IV acute GVHD within 6 weeks after the first ALT-803 dose Maximum Tolerated Dose (MTD) is defined as the dose level where ≤ 1 out of 6 patients has DLT during the first treatment cycle
Time Frame4 weeks

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group TitleALT-803, IV, 1 mcg/kgALT-803, IV, 3 mcg/kgALT-803, IV, 6 mcg/kgALT-803, IV, 10 mcg/kgALT-803, SQ, 6 mcg/kgALT-803, SQ, 10 mcg/kg
Arm/Group DescriptionWeekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose subcutaneously, once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose , subcutaneously, once a week for 4 weeks.
Measure Participants634389
Count of Participants [Participants]
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
2. Primary Outcome
TitleNumber of Participants Experiencing Potential Efficacy of ALT 803
DescriptionThe potential efficacy of ALT-803 in this patient population is measured by the responses based on bone marrow examination 1 and 3 months after the last dose of ALT-803. Response was defined as follows: for AML and myelodysplastic syndromes (MDS) using the International Working Group modified criteria, non-Hodgkin lymphoma, and multiple myeloma using the International Myeloma Working Group Uniform Response Criteria, and acute lymphoblastic leukemia using protocol-specified criteria.
Time Frame4 months

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group TitleALT-803, IV, 1 mcg/kgALT-803, IV, 3 mcg/kgALT-803, IV, 6 mcg/kgALT-803, IV, 10 mcg/kgALT-803, SQ, 6 mcg/kgALT-803, SQ, 10 mcg/kg
Arm/Group DescriptionWeekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose subcutaneously, once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose , subcutaneously, once a week for 4 weeks.
Measure Participants634389
Count of Participants [Participants]
0
0%
1
33.3%
2
50%
0
0%
1
12.5%
0
0%
3. Secondary Outcome
TitleNumber of Participants With Excessive Toxicity
DescriptionTo evaluate the safety of the ALT-803 when administered on this schedule. Excessive toxicity is defined as having a grade 3-5 non-hematologic, non-relapse and non-infectious toxicity (except fevers alone) based on the NCI's CTCAE version 4.
Time Frame4 weeks

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group TitleALT-803, IV, 1 mcg/kgALT-803, IV, 3 mcg/kgALT-803, IV, 6 mcg/kgALT-803, IV, 10 mcg/kgALT-803, SQ, 6 mcg/kgALT-803, SQ, 10 mcg/kg
Arm/Group DescriptionWeekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose subcutaneously, once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose , subcutaneously, once a week for 4 weeks.
Measure Participants634389
Count of Participants [Participants]
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%
4. Secondary Outcome
TitleNumber of Participants With Incidence of Acute Graft Versus Host Disease
Description
Time Frame100 days

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group TitleALT-803, IV, 1 mcg/kgALT-803, IV, 3 mcg/kgALT-803, IV, 6 mcg/kgALT-803, IV, 10 mcg/kgALT-803, SQ, 6 mcg/kgALT-803, SQ, 10 mcg/kg
Arm/Group DescriptionWeekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose subcutaneously, once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose , subcutaneously, once a week for 4 weeks.
Measure Participants634389
Count of Participants [Participants]
2
33.3%
1
33.3%
1
25%
1
33.3%
1
12.5%
3
33.3%
5. Secondary Outcome
TitleNumber of Participants With Incidence of Chronic Graft Versus Host Disease
Description
Time Frame1 year

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group TitleALT-803, IV, 1 mcg/kgALT-803, IV, 3 mcg/kgALT-803, IV, 6 mcg/kgALT-803, IV, 10 mcg/kgALT-803, SQ, 6 mcg/kgALT-803, SQ, 10 mcg/kg
Arm/Group DescriptionWeekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose subcutaneously, once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose , subcutaneously, once a week for 4 weeks.
Measure Participants634389
Count of Participants [Participants]
0
0%
0
0%
0
0%
0
0%
0
0%
0
0%

Adverse Events

Time FrameTwo years
Adverse Event Reporting Description
Arm/Group TitleALT-803, IV, 1 mcg/kgALT-803, IV, 3 mcg/kgALT-803, IV, 6 mcg/kgALT-803, IV, 10 mcg/kgALT-803, SQ, 6 mcg/kgALT-803, SQ, 10 mcg/kg
Arm/Group DescriptionWeekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose subcutaneously, once a week for 4 weeks.Weekly dose of ALT-803 at assigned dose , subcutaneously, once a week for 4 weeks.
All Cause Mortality
ALT-803, IV, 1 mcg/kgALT-803, IV, 3 mcg/kgALT-803, IV, 6 mcg/kgALT-803, IV, 10 mcg/kgALT-803, SQ, 6 mcg/kgALT-803, SQ, 10 mcg/kg
Affected / at Risk (%)# EventsAffected / at Risk (%)# EventsAffected / at Risk (%)# EventsAffected / at Risk (%)# EventsAffected / at Risk (%)# EventsAffected / at Risk (%)# Events
Total3/6 (50%) 2/3 (66.7%) 4/4 (100%) 2/3 (66.7%) 8/8 (100%) 8/9 (88.9%)
Serious Adverse Events
ALT-803, IV, 1 mcg/kgALT-803, IV, 3 mcg/kgALT-803, IV, 6 mcg/kgALT-803, IV, 10 mcg/kgALT-803, SQ, 6 mcg/kgALT-803, SQ, 10 mcg/kg
Affected / at Risk (%)# EventsAffected / at Risk (%)# EventsAffected / at Risk (%)# EventsAffected / at Risk (%)# EventsAffected / at Risk (%)# EventsAffected / at Risk (%)# Events
Total1/6 (16.7%) 1/3 (33.3%) 0/4 (0%) 0/3 (0%) 6/8 (75%) 6/9 (66.7%)
Blood and lymphatic system disorders
Febrile neutropenia0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 02/8 (25%) 25/9 (55.6%) 5
General disorders
Fever0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 10/9 (0%) 0
Infections and infestations
Catheter related infection1/6 (16.7%) 10/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 00/9 (0%) 0
Bacteremia0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 11/9 (11.1%) 1
Lung infection0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 10/9 (0%) 0
Sepsis0/6 (0%) 01/3 (33.3%) 10/4 (0%) 00/3 (0%) 01/8 (12.5%) 10/9 (0%) 0
Shingles0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Musculoskeletal and connective tissue disorders
Generalized muscle weakness0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 02/8 (25%) 20/9 (0%) 0
Nervous system disorders
Intracranial hemorrhage0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 20/9 (0%) 0
Respiratory, thoracic and mediastinal disorders
Hypoxia0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 10/9 (0%) 0
Skin and subcutaneous tissue disorders
Cellulitis0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Vascular disorders
Hypotension0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Vascular disorders0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 10/9 (0%) 0
Other (Not Including Serious) Adverse Events
ALT-803, IV, 1 mcg/kgALT-803, IV, 3 mcg/kgALT-803, IV, 6 mcg/kgALT-803, IV, 10 mcg/kgALT-803, SQ, 6 mcg/kgALT-803, SQ, 10 mcg/kg
Affected / at Risk (%)# EventsAffected / at Risk (%)# EventsAffected / at Risk (%)# EventsAffected / at Risk (%)# EventsAffected / at Risk (%)# EventsAffected / at Risk (%)# Events
Total4/6 (66.7%) 2/3 (66.7%) 2/4 (50%) 2/3 (66.7%) 8/8 (100%) 9/9 (100%)
Blood and lymphatic system disorders
Anemia0/6 (0%) 01/3 (33.3%) 11/4 (25%) 20/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Febrile neutropenia1/6 (16.7%) 11/3 (33.3%) 10/4 (0%) 01/3 (33.3%) 32/8 (25%) 26/9 (66.7%) 12
Cardiac disorders
Atrial flutter1/6 (16.7%) 10/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 00/9 (0%) 0
Sinus tachycardia0/6 (0%) 00/3 (0%) 01/4 (25%) 10/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Gastrointestinal disorders
Abdominal distension0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 10/9 (0%) 0
Abdominal pain0/6 (0%) 01/3 (33.3%) 10/4 (0%) 00/3 (0%) 00/8 (0%) 03/9 (33.3%) 3
Constipation0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Diarrhea0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 30/9 (0%) 0
Dry mouth0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Dark stools - intermittent0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 00/9 (0%) 0
Mucositis oral0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Nausea0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Oral pain0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Gastroesophageal reflux disease1/6 (16.7%) 10/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 00/9 (0%) 0
General disorders
Chills0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 3
Edema face0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Fatigue0/6 (0%) 00/3 (0%) 01/4 (25%) 10/3 (0%) 03/8 (37.5%) 52/9 (22.2%) 2
Fever0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 02/8 (25%) 20/9 (0%) 0
General disorders and administration site conditions - Other, specify0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 10/9 (0%) 0
Injection site reaction0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 21/9 (11.1%) 1
Pain0/6 (0%) 00/3 (0%) 00/4 (0%) 01/3 (33.3%) 10/8 (0%) 01/9 (11.1%) 1
Infections and infestations
Catheter related infection1/6 (16.7%) 10/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 00/9 (0%) 0
Bacteremia0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 00/9 (0%) 0
Sepsis0/6 (0%) 01/3 (33.3%) 10/4 (0%) 00/3 (0%) 01/8 (12.5%) 10/9 (0%) 0
Skin infection0/6 (0%) 00/3 (0%) 01/4 (25%) 10/3 (0%) 00/8 (0%) 00/9 (0%) 0
Upper respiratory infection0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Lung infection0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 20/9 (0%) 0
Injury, poisoning and procedural complications
Fall0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 10/9 (0%) 0
Biopsy site oozing0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 00/9 (0%) 0
Investigations
Activated partial thromboplastin time prolonged0/6 (0%) 00/3 (0%) 01/4 (25%) 10/3 (0%) 00/8 (0%) 00/9 (0%) 0
Alanine aminotransferase increased0/6 (0%) 01/3 (33.3%) 21/4 (25%) 10/3 (0%) 00/8 (0%) 00/9 (0%) 0
Alkaline phosphatase increased0/6 (0%) 00/3 (0%) 01/4 (25%) 10/3 (0%) 00/8 (0%) 00/9 (0%) 0
Aspartate aminotransferase increased0/6 (0%) 01/3 (33.3%) 21/4 (25%) 20/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Creatinine increased0/6 (0%) 01/3 (33.3%) 10/4 (0%) 00/3 (0%) 00/8 (0%) 00/9 (0%) 0
INR increased0/6 (0%) 00/3 (0%) 01/4 (25%) 20/3 (0%) 00/8 (0%) 00/9 (0%) 0
Neutrophil count decreased0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 20/9 (0%) 0
White blood cell decreased0/6 (0%) 01/3 (33.3%) 11/4 (25%) 20/3 (0%) 00/8 (0%) 00/9 (0%) 0
Metabolism and nutrition disorders
Anorexia0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 21/9 (11.1%) 1
Hyperuricemia1/6 (16.7%) 10/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 00/9 (0%) 0
Hypoalbuminemia0/6 (0%) 00/3 (0%) 01/4 (25%) 10/3 (0%) 01/8 (12.5%) 44/9 (44.4%) 5
Hypocalcemia0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 02/8 (25%) 70/9 (0%) 0
Hypokalemia0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 10/9 (0%) 0
Hypomagnesemia0/6 (0%) 01/3 (33.3%) 10/4 (0%) 00/3 (0%) 01/8 (12.5%) 11/9 (11.1%) 1
Hyponatremia0/6 (0%) 00/3 (0%) 01/4 (25%) 10/3 (0%) 03/8 (37.5%) 42/9 (22.2%) 2
Musculoskeletal and connective tissue disorders
Back pain0/6 (0%) 01/3 (33.3%) 10/4 (0%) 01/3 (33.3%) 11/8 (12.5%) 11/9 (11.1%) 1
Pain in extremity0/6 (0%) 00/3 (0%) 00/4 (0%) 01/3 (33.3%) 10/8 (0%) 00/9 (0%) 0
Generalized muscle weakness0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 02/8 (25%) 20/9 (0%) 0
Muscle weakness left-sided0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 10/9 (0%) 0
Nervous system disorders
Headache0/6 (0%) 01/3 (33.3%) 10/4 (0%) 00/3 (0%) 02/8 (25%) 42/9 (22.2%) 2
Intracranial hemorrhage0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 20/9 (0%) 0
Paresthesia0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Peripheral sensory neuropathy0/6 (0%) 01/3 (33.3%) 10/4 (0%) 00/3 (0%) 00/8 (0%) 00/9 (0%) 0
Syncope0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 2
Psychiatric disorders
Confusion0/6 (0%) 00/3 (0%) 01/4 (25%) 10/3 (0%) 02/8 (25%) 20/9 (0%) 0
Renal and urinary disorders
Acute kidney injury0/6 (0%) 00/3 (0%) 01/4 (25%) 10/3 (0%) 00/8 (0%) 00/9 (0%) 0
Respiratory, thoracic and mediastinal disorders
Cough0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Epistaxis0/6 (0%) 01/3 (33.3%) 20/4 (0%) 00/3 (0%) 00/8 (0%) 00/9 (0%) 0
Hypoxia0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 11/9 (11.1%) 1
Skin and subcutaneous tissue disorders
Rash maculo-papular0/6 (0%) 00/3 (0%) 00/4 (0%) 01/3 (33.3%) 11/8 (12.5%) 11/9 (11.1%) 1
Rash0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 00/9 (0%) 0
Vascular disorders
Flushing0/6 (0%) 00/3 (0%) 01/4 (25%) 10/3 (0%) 00/8 (0%) 00/9 (0%) 0
Hot flashes0/6 (0%) 01/3 (33.3%) 10/4 (0%) 00/3 (0%) 00/8 (0%) 00/9 (0%) 0
Hypertension0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 00/8 (0%) 01/9 (11.1%) 1
Hypotension0/6 (0%) 00/3 (0%) 00/4 (0%) 00/3 (0%) 01/8 (12.5%) 43/9 (33.3%) 4

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact

Name/TitleDr. Jeffrey Miller
OrganizationMasonic Cancer Center, University of Minnesota
Phone612-626-4024
Emailmille011@umn.edu
Responsible Party:
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT01885897
Other Study ID Numbers:
  • 2012LS023
  • HM2013-12
First Posted:
Jun 25, 2013
Last Update Posted:
Aug 12, 2020
Last Verified:
Jul 1, 2020